135 related articles for article (PubMed ID: 28767070)
1. Nuclear factor (erythroid-derived 2)-like 2 regulates drug resistance in pancreatic cancer cells.
Hong YB; Kang HJ; Kwon SY; Kim HJ; Kwon KY; Cho CH; Lee JM; Kallakury BV; Bae I
Pancreas; 2010 May; 39(4):463-72. PubMed ID: 20118824
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin resistance driver claspin is a target for immunotherapy in urothelial carcinoma.
Yamada S; Miyata H; Isono M; Hori K; Yanagawa J; Murai A; Minowa T; Mizue Y; Sasaki K; Murata K; Tokita S; Nakatsugawa M; Iwabuchi S; Hashimoto S; Kubo T; Kanaseki T; Tsukahara T; Abe T; Shinohara N; Hirohashi Y; Torigoe T
Cancer Immunol Immunother; 2023 Jul; 72(7):2057-2065. PubMed ID: 36795123
[TBL] [Abstract][Full Text] [Related]
3. Evolution of cisplatin resistance through coordinated metabolic reprogramming of the cellular reductive state.
Yu W; Chen Y; Putluri N; Osman A; Coarfa C; Putluri V; Kamal AHM; Asmussen JK; Katsonis P; Myers JN; Lai SY; Lu W; Stephan CC; Powell RT; Johnson FM; Skinner HD; Kazi J; Ahmed KM; Hu L; Threet A; Meyer MD; Bankson JA; Wang T; Davis J; Parker KR; Harris MA; Baek ML; Echeverria GV; Qi X; Wang J; Frederick AI; Walsh AJ; Lichtarge O; Frederick MJ; Sandulache VC
Br J Cancer; 2023 Jun; 128(11):2013-2024. PubMed ID: 37012319
[TBL] [Abstract][Full Text] [Related]
4. Targeted Inhibition of Anti-Inflammatory Regulator Nrf2 Results in Breast Cancer Retardation In Vitro and In Vivo.
Bovilla VR; Kuruburu MG; Bettada VG; Krishnamurthy J; Sukocheva OA; Thimmulappa RK; Shivananju NS; Balakrishna JP; Madhunapantula SV
Biomedicines; 2021 Aug; 9(9):. PubMed ID: 34572304
[TBL] [Abstract][Full Text] [Related]
5. A PGAM5-KEAP1-Nrf2 complex is required for stress-induced mitochondrial retrograde trafficking.
O'Mealey GB; Plafker KS; Berry WL; Janknecht R; Chan JY; Plafker SM
J Cell Sci; 2017 Oct; 130(20):3467-3480. PubMed ID: 28839075
[TBL] [Abstract][Full Text] [Related]
6. Regulation of SQSTM1/p62 via UBA domain ubiquitination and its role in disease.
Lee Y; Weihl CC
Autophagy; 2017 Sep; 13(9):1615-1616. PubMed ID: 28812433
[TBL] [Abstract][Full Text] [Related]
7. Nuclear factor (erythroid-derived 2)-like 2 (NRF2) drug discovery: Biochemical toolbox to develop NRF2 activators by reversible binding of Kelch-like ECH-associated protein 1 (KEAP1).
Bresciani A; Missineo A; Gallo M; Cerretani M; Fezzardi P; Tomei L; Cicero DO; Altamura S; Santoprete A; Ingenito R; Bianchi E; Pacifici R; Dominguez C; Munoz-Sanjuan I; Harper S; Toledo-Sherman L; Park LC
Arch Biochem Biophys; 2017 Oct; 631():31-41. PubMed ID: 28801166
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the Potent, Selective Nrf2 Activator, 3-(Pyridin-3-Ylsulfonyl)-5-(Trifluoromethyl)-2
Yonchuk JG; Foley JP; Bolognese BJ; Logan G; Wixted WE; Kou JP; Chalupowicz DG; Feldser HG; Sanchez Y; Nie H; Callahan JF; Kerns JK; Podolin PL
J Pharmacol Exp Ther; 2017 Oct; 363(1):114-125. PubMed ID: 28790194
[TBL] [Abstract][Full Text] [Related]
9. Tumorigenic effects of human mesenchymal stromal cells and fibroblasts on bladder cancer cells.
Frerichs LM; Frerichs B; Petzsch P; Köhrer K; Windolf J; Bittersohl B; Hoffmann MJ; Grotheer V
Front Oncol; 2023; 13():1228185. PubMed ID: 37781195
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic Priming and Development of New Combination Therapy Approaches.
Meneceur S; Grunewald CM; Niegisch G; Hoffmann MJ
Methods Mol Biol; 2023; 2684():259-281. PubMed ID: 37410240
[TBL] [Abstract][Full Text] [Related]
11. Signaling pathways of oxidative stress response: the potential therapeutic targets in gastric cancer.
Liu Y; Shi Y; Han R; Liu C; Qin X; Li P; Gu R
Front Immunol; 2023; 14():1139589. PubMed ID: 37143652
[TBL] [Abstract][Full Text] [Related]
12. Arbutin-modified microspheres prevent osteoarthritis progression by mobilizing local anti-inflammatory and antioxidant responses.
Jin J; Liu Y; Jiang C; Shen Y; Chu G; Liu C; Jiang L; Huang G; Qin Y; Zhang Y; Zhang C; Wang Y
Mater Today Bio; 2022 Dec; 16():100370. PubMed ID: 35937573
[TBL] [Abstract][Full Text] [Related]
13. Sinomenine activation of Nrf2 signaling prevents inflammation and cerebral injury in a mouse model of ischemic stroke.
Bi F; Zhang Y; Liu W; Xie K
Exp Ther Med; 2021 Jun; 21(6):647. PubMed ID: 33968178
[TBL] [Abstract][Full Text] [Related]
14. Distinctive mutational spectrum and karyotype disruption in long-term cisplatin-treated urothelial carcinoma cell lines.
Skowron MA; Petzsch P; Hardt K; Wagner N; Beier M; Stepanow S; Drechsler M; Rieder H; Köhrer K; Niegisch G; Hoffmann MJ; Schulz WA
Sci Rep; 2019 Oct; 9(1):14476. PubMed ID: 31597922
[TBL] [Abstract][Full Text] [Related]
15. Stimulated upregulation of
Cesna V; Sukovas A; Jasukaitiene A; Silkuniene G; Paskauskas S; Dambrauskas Z; Gulbinas A
Oncol Lett; 2019 Aug; 18(2):1961-1968. PubMed ID: 31423266
[TBL] [Abstract][Full Text] [Related]
16. NRF2 Is One of the Players Involved in Bone Marrow Mediated Drug Resistance in Multiple Myeloma.
Yen CH; Hsiao HH
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30405034
[TBL] [Abstract][Full Text] [Related]
17. A Complementary Chemical and Genomic Screening Approach for Druggable Targets in the Nrf2 Pathway and Small Molecule Inhibitors to Overcome Cancer Cell Drug Resistance.
Matthews JH; Liang X; Paul VJ; Luesch H
ACS Chem Biol; 2018 May; 13(5):1189-1199. PubMed ID: 29565554
[TBL] [Abstract][Full Text] [Related]
18. Multifaceted Mechanisms of Cisplatin Resistance in Long-Term Treated Urothelial Carcinoma Cell Lines.
Skowron MA; Melnikova M; van Roermund JGH; Romano A; Albers P; Thomale J; Schulz WA; Niegisch G; Hoffmann MJ
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29462944
[TBL] [Abstract][Full Text] [Related]
19. Various Mechanisms Involve the Nuclear Factor (Erythroid-Derived 2)-Like (NRF2) to Achieve Cytoprotection in Long-Term Cisplatin-Treated Urothelial Carcinoma Cell Lines.
Skowron MA; Niegisch G; Albrecht P; van Koeveringe G; Romano A; Albers P; Schulz WA; Hoffmann MJ
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28767070
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
